References
Wee S, Pascual M, Eason JD, et al. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation 1997 Feb 27; 63: 570–7
Moreland LW, Saway PA, Jacobs C, et al. Soluble tumor necrosis factor receptor (sTNFR): results of a phase I dose-escalation study in patients with rheumatoid arthritis. Clin Res 1994 Apr; 42: 312A
Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337: 141–7
ENBREL study suggests six-month administration is safe: preliminary results from ongoing safety study presented at ACR meeting. PR Newswire [online] 1997 Apr 11; 2 pages. Available from URL: http://www.newspage.com
Moreland LW, Margolies G, Heck Jr LW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996 Nov; 23: 1849–55
Weinblatt M, Moreland LW, Schiff MH, et al. Long term and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor P75 fusion protein (TNFR:FC; Enbrel (Rm)). Arthritis Rheum 1997 Sep; 40 Suppl.: 126
Moreland LW, Baumgartner SW, Tindall EA, et al. Long term treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 FC fusion protein (Enbrel Rm). J Investig Med 1998 Mar; 46: 229
Suffredini AF, Reda D, Agosti J, et al. Antiinflammatory effects of recombinant tumor necrosis factor receptor in normal humans following intravenous endotoxin. Am J Respir Crit Care Med 1994 Apr; 149 (4 Pt 2): 240
Rights and permissions
About this article
Cite this article
Etanercept. Drugs R&D 1, 258–261 (1999). https://doi.org/10.2165/00126839-199901030-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00016